LAG3 Expression in Triple Negative Breast Cancer

Last updated: February 6, 2024
Sponsor: Samsung Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Breast Cancer

Treatment

LAG-3 expression / immune checkpoint protein expression

Clinical Study ID

NCT06259162
LAG3_Breast
  • Female
  • Accepts Healthy Volunteers

Study Summary

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Planned neoadjuvant chemotherapy
  • Triple negative breast cancer

Exclusion

Exclusion Criteria:

  • HER2-positive breast cancer
  • Hormone receptor positive breast cancer

Study Design

Total Participants: 128
Treatment Group(s): 1
Primary Treatment: LAG-3 expression / immune checkpoint protein expression
Phase:
Study Start date:
November 18, 2022
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • Ji-Yeon Kim

    Seoul, 06351
    Korea, Republic of

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.